Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: Possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer

Kimberly R. Kalli, Sarah V. Bradley, Susanne Fuchshuber, Cheryl A Conover

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives. Development of targeted therapeutics for ovarian cancer requires a basic understanding of ovarian epithelial carcinoma cell biology. The role of estrogen and epidermal growth factor (EGF) in control of cell growth was investigated in a panel of ovarian carcinoma lines. Methods. EGF receptor (EGFR) was detected by flow cytometry and estrogen receptor (ER) by Northern blot. Western blotting and [ 3H]thymidine incorporation were used to determine receptor activation and the effects of ligand exposure and growth factor antagonists, including the antineoplastic agent, suramin, on cell growth. Results. Only one cell line, OV266, expressed ER and responded to β-estradiol with increases in DNA synthesis and cell proliferation that could be blocked by the pure antiestrogen ICI 182,780. All cell lines possessed functional EGFR as measured by flow cytometry and phosphorylation of the receptor and mitogen-activated protein kinase after EGF treatment, but only two cell lines (OV177 and OV266) proliferated in response to exogenous EGF. Suramin had limited effectiveness in inhibiting growth in four of five cell lines and had a striking dose-dependent stimulatory effect on OV266 cell growth. The proliferative response to suramin could be inhibited with EGFR antagonists. Conclusion. Cultured epithelial ovarian carcinoma cell lines express EGFR (5/5) and can express ER (1/5). Differential growth responses to EGF were observed despite uniform receptor and MAPK activation. Unexpectedly, the antineoplastic agent suramin increased growth of ER positive ovarian carcinoma cells in an EGFR-dependent manner. These studies provide insight into the complex interactions of these systems in control of ovarian cancer cell growth.

Original languageEnglish (US)
Pages (from-to)705-712
Number of pages8
JournalGynecologic Oncology
Volume94
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Suramin
Epidermal Growth Factor
Estrogen Receptors
Antineoplastic Agents
Ovarian Neoplasms
Epidermal Growth Factor Receptor
Carcinoma
Growth
Cell Line
Flow Cytometry
Estrogen Receptor Modulators
Estrogen Receptor alpha
Mitogen-Activated Protein Kinases
Northern Blotting
Thymidine
Cell Biology
Estradiol
Intercellular Signaling Peptides and Proteins
Estrogens
Western Blotting

Keywords

  • EGF receptor
  • Estrogen receptor
  • Ovarian cancer
  • Suramin

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

@article{4923dc473bf143afb7d367bc452f0daa,
title = "Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: Possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer",
abstract = "Objectives. Development of targeted therapeutics for ovarian cancer requires a basic understanding of ovarian epithelial carcinoma cell biology. The role of estrogen and epidermal growth factor (EGF) in control of cell growth was investigated in a panel of ovarian carcinoma lines. Methods. EGF receptor (EGFR) was detected by flow cytometry and estrogen receptor (ER) by Northern blot. Western blotting and [ 3H]thymidine incorporation were used to determine receptor activation and the effects of ligand exposure and growth factor antagonists, including the antineoplastic agent, suramin, on cell growth. Results. Only one cell line, OV266, expressed ER and responded to β-estradiol with increases in DNA synthesis and cell proliferation that could be blocked by the pure antiestrogen ICI 182,780. All cell lines possessed functional EGFR as measured by flow cytometry and phosphorylation of the receptor and mitogen-activated protein kinase after EGF treatment, but only two cell lines (OV177 and OV266) proliferated in response to exogenous EGF. Suramin had limited effectiveness in inhibiting growth in four of five cell lines and had a striking dose-dependent stimulatory effect on OV266 cell growth. The proliferative response to suramin could be inhibited with EGFR antagonists. Conclusion. Cultured epithelial ovarian carcinoma cell lines express EGFR (5/5) and can express ER (1/5). Differential growth responses to EGF were observed despite uniform receptor and MAPK activation. Unexpectedly, the antineoplastic agent suramin increased growth of ER positive ovarian carcinoma cells in an EGFR-dependent manner. These studies provide insight into the complex interactions of these systems in control of ovarian cancer cell growth.",
keywords = "EGF receptor, Estrogen receptor, Ovarian cancer, Suramin",
author = "Kalli, {Kimberly R.} and Bradley, {Sarah V.} and Susanne Fuchshuber and Conover, {Cheryl A}",
year = "2004",
month = "9",
doi = "10.1016/j.ygyno.2004.05.059",
language = "English (US)",
volume = "94",
pages = "705--712",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation

T2 - Possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer

AU - Kalli, Kimberly R.

AU - Bradley, Sarah V.

AU - Fuchshuber, Susanne

AU - Conover, Cheryl A

PY - 2004/9

Y1 - 2004/9

N2 - Objectives. Development of targeted therapeutics for ovarian cancer requires a basic understanding of ovarian epithelial carcinoma cell biology. The role of estrogen and epidermal growth factor (EGF) in control of cell growth was investigated in a panel of ovarian carcinoma lines. Methods. EGF receptor (EGFR) was detected by flow cytometry and estrogen receptor (ER) by Northern blot. Western blotting and [ 3H]thymidine incorporation were used to determine receptor activation and the effects of ligand exposure and growth factor antagonists, including the antineoplastic agent, suramin, on cell growth. Results. Only one cell line, OV266, expressed ER and responded to β-estradiol with increases in DNA synthesis and cell proliferation that could be blocked by the pure antiestrogen ICI 182,780. All cell lines possessed functional EGFR as measured by flow cytometry and phosphorylation of the receptor and mitogen-activated protein kinase after EGF treatment, but only two cell lines (OV177 and OV266) proliferated in response to exogenous EGF. Suramin had limited effectiveness in inhibiting growth in four of five cell lines and had a striking dose-dependent stimulatory effect on OV266 cell growth. The proliferative response to suramin could be inhibited with EGFR antagonists. Conclusion. Cultured epithelial ovarian carcinoma cell lines express EGFR (5/5) and can express ER (1/5). Differential growth responses to EGF were observed despite uniform receptor and MAPK activation. Unexpectedly, the antineoplastic agent suramin increased growth of ER positive ovarian carcinoma cells in an EGFR-dependent manner. These studies provide insight into the complex interactions of these systems in control of ovarian cancer cell growth.

AB - Objectives. Development of targeted therapeutics for ovarian cancer requires a basic understanding of ovarian epithelial carcinoma cell biology. The role of estrogen and epidermal growth factor (EGF) in control of cell growth was investigated in a panel of ovarian carcinoma lines. Methods. EGF receptor (EGFR) was detected by flow cytometry and estrogen receptor (ER) by Northern blot. Western blotting and [ 3H]thymidine incorporation were used to determine receptor activation and the effects of ligand exposure and growth factor antagonists, including the antineoplastic agent, suramin, on cell growth. Results. Only one cell line, OV266, expressed ER and responded to β-estradiol with increases in DNA synthesis and cell proliferation that could be blocked by the pure antiestrogen ICI 182,780. All cell lines possessed functional EGFR as measured by flow cytometry and phosphorylation of the receptor and mitogen-activated protein kinase after EGF treatment, but only two cell lines (OV177 and OV266) proliferated in response to exogenous EGF. Suramin had limited effectiveness in inhibiting growth in four of five cell lines and had a striking dose-dependent stimulatory effect on OV266 cell growth. The proliferative response to suramin could be inhibited with EGFR antagonists. Conclusion. Cultured epithelial ovarian carcinoma cell lines express EGFR (5/5) and can express ER (1/5). Differential growth responses to EGF were observed despite uniform receptor and MAPK activation. Unexpectedly, the antineoplastic agent suramin increased growth of ER positive ovarian carcinoma cells in an EGFR-dependent manner. These studies provide insight into the complex interactions of these systems in control of ovarian cancer cell growth.

KW - EGF receptor

KW - Estrogen receptor

KW - Ovarian cancer

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=4444293285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444293285&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.05.059

DO - 10.1016/j.ygyno.2004.05.059

M3 - Article

C2 - 15350362

AN - SCOPUS:4444293285

VL - 94

SP - 705

EP - 712

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -